ライフサイエンスコーパス: adenosine 5'-diphosphate

1 platelet activation in vitro in response to adenosine 5'-diphosphate.

2 mong a panel of substrate analogs, including adenosine 5'-diphosphate.

3 n complex with the full agonist 2-methylthio-adenosine-5'-diphosphate (2MeSADP, a close analogue of e

4 numerous agonists (collagen-related peptide, adenosine 5'-diphosphate, A23187, thrombin, or U46619).

5 This released adenosine-5'-diphosphate, acting through P2Y(12), is cri

6 In adenosine 5'-diphosphate-activated HMEC-1, also sera fro

7 tions of adenosine 5'-triphosphate (ATP) and adenosine 5'-diphosphate (ADP) and guanosine conformatio

8 the Dictyostelium motor domain with bound Mg.adenosine 5'-diphosphate (ADP) and P(i), modeled upon th

9 ctivities by long-term culture with 2 mmol/L adenosine 5'-diphosphate (ADP) and Pi sensitized both dr

10 rioles to endothelium-dependent vasodilators adenosine 5'-diphosphate (ADP) and substance P and the e

11 Adenosine 5'-diphosphate (ADP) induces platelet aggregat

12 greater extent compared with the addition of adenosine 5'-diphosphate (ADP) or adenosine 5'-monophosp

13 nhibition of platelet aggregation induced by adenosine 5'-diphosphate (ADP) or low concentrations of

14 tein accumulation, as does either inhibiting adenosine 5'-diphosphate (ADP) P2Y12receptors or reducin

15 blood and flow conditions, it was shown that adenosine 5'-diphosphate (ADP) receptors P2Y(12) and P2Y

16 udlak syndrome (HPS) as a model to show that adenosine 5'-diphosphate (ADP) released by dense granule

17 High agonist doses or supplemental adenosine 5'-diphosphate (ADP) restored normal alpha gra

18 hate (cAMP) in the platelet cytosol, such as adenosine 5'-diphosphate (ADP) secreted from dense granu

19 block polymerization was crystallized in the adenosine 5'-diphosphate (ADP) state, and the structure

20 upled receptor P2Y1 (P2Y1 R) is activated by adenosine 5'-diphosphate (ADP) to induce platelet activa

21 It degrades adenosine 5'-diphosphate (ADP), a main platelet activati

22 ists, but they enhanced response to low-dose adenosine 5'-diphosphate (ADP), epinephrine, or serotoni

23 nd the apparent inhibition constant (Ki) for adenosine 5'-diphosphate (ADP), which compared favorably

24 on associated with a lower affinity for DNA (Adenosine 5'-diphosphate (ADP)-bound).

25 Adenosine 5'-diphosphate (ADP)-glucose pyrophosphorylase

26 ticagrelor promoted a greater inhibition of adenosine 5'-diphosphate (ADP)-induced Ca(2+) release in

27 The enzyme poly(adenosine 5'-diphosphate (ADP)-ribose) polymerase (PARP-

28 ions, little is known about the role of poly[adenosine 5'-diphosphate (ADP)-ribose] in chromatin remo

29 hat the Dombrock molecule is a member of the adenosine 5'-diphosphate (ADP)-ribosyltransferase ectoen

30 ected by addition of subthreshold amounts of adenosine 5'-diphosphate (ADP).

31 revealed enhanced binding in the presence of adenosine 5'-diphosphate (ADP).

32 ciated with increased platelet reactivity to adenosine 5'-diphosphate (ADP).

33 1-ATPase respectively regulate mitochondrial adenosine 5'-diphosphate (ADP)/ATP exchange and ADP-phos

34 cross-selectivity was demonstrated with the adenosine-5'-diphosphate (ADP) imprinting and ATP discri

35 telet agonists (U-46619, alpha-thrombin, and adenosine 5'-diphosphate [ADP]) induced a [Ca2+]i signal

36 Poly(adenosine 5'-diphosphate [ADP]-ribose)-polymerase (PARP)

37 inant wild-type (WT) Rhodobacter sphaeroides adenosine 5'-diphosphate-(ADP)-glucose pyrophosphorylase

38 nucleotidase inhibitor, alpha,beta-methylene adenosine 5'-diphosphate (AMP-CP), and a competitive sub

39 y [beta-32P]-8-(4-bromo-2, 3-dioxo-butylthio)adenosine-5'-diphosphate, an ADP-affinity analog that se

40 displayed reduced aggregation in response to adenosine 5'-diphosphate and epinephrine, but variable a

41 e, while the shell was heavily influenced by adenosine 5'-diphosphate and regulators of Gi2-mediated

42 Moreover, feedback agonists adenosine 5'-diphosphate and thromboxane A2 are mandator

43 and P2ry14-purinergic receptors activated by adenosine 5-diphosphate and UDP-sugars, respectively-wer

44 stimulation elicited by 10 nM 2-(methylthio)adenosine 5'-diphosphate (antagonist effect).

45 nucleotidase inhibitor alpha, beta-methylene adenosine-5'-diphosphate (APCP) abrogates completely the

46 on in platelet sensitivity to aggregation by adenosine 5'-diphosphate, arachidonic acid, and phorbol

47 Finally, the location of the adenosine 5'-diphosphate binding site within the nucleot

48 nucleotidase inhibitor (alpha,beta-methylene adenosine-5'-diphosphate) blocked the effect of MTX, ade

49 ranules and GPIIb-IIIa activation induced by adenosine 5'-diphosphate, convulxin, and thrombin; (3) s

50 Other nucleotide-glucose compounds (adenosine-5'-diphosphate-D-glucose, guanosine-5'-diphosp

51 x status of cPABP through redox potential or adenosine 5'-diphosphate-dependent phosphorylation.

52 aride treatment reduced the rate of state 3 (adenosine 5'-diphosphate-dependent) respiration, especia

53 Adenosine, adenosine 5'-monophosphate, or adenosine 5'-diphosphate did not excite these fibres (n

54 he properties of the starch synthesis enzyme adenosine 5'-diphosphate-glucose pyrophosphorylase (AGPa

55 ex with three inhibitors: ADP-ribose (ADPR), adenosine 5'-diphosphate (hydroxymethyl)pyrrolidinediol

56 tly phosphorylated by thrombin compared with adenosine 5'-diphosphate in platelets.

57 ibition), and increased the rate of state 4 (adenosine 5'-diphosphate-independent) respiration, refle

58 vasodilatation and abolished substance P- or adenosine 5 diphosphate-induced relaxation (P<0.05), but

59 ffinity for 2'-(3')-O-(N-methylanthraniloyl) adenosine 5'-diphosphate (mant ADP), similar to the sing

60 Finally, ADP, 2'-O-(N-methylanthraniloyl)-adenosine-5'-diphosphate (MANT-ADP), and adenosine 5'-O-

61 ates (MANT-ADP, 3',2'-O-(N-methylantraniloyl)adenosine-5'-diphosphate; MANT-GDP, 3',2'-O(N-methylantr

62 t ADP analog, 2'(3')-O-(N-methylanthraniloyl)adenosine 5'-diphosphate (mantADP) from the active site

63 nt analogue 2'-(3')-O-(N-methylanthraniloyl) adenosine 5'-diphosphate (mantADP) to report microtubule

64 Studies of patients with defective adenosine-5'-diphosphate mediated aggregation, as well a

65 ll, releasing its energy via hydrolysis into adenosine 5'-diphosphate or ADP.

66 othelial growth factor (VEGF) in response to adenosine 5'-diphosphate or tumor cells (MCF-7 cells) an

67 t bind to adenosine, adenosine triphosphate, adenosine 5'-diphosphate, or structurally related drugs.

68 The hydrolyzed product, adenosine 5'-diphosphate orients the surface of GlnK for

69 metabolic function (adenosine 5-triphosphate/adenosine 5-diphosphate ratio, nicotinamide adenine dinu

70 Structures of FDH.adenosine 5'-diphosphate ribose (ADP-ribose) and E67L.NA

71 Cyclic adenosine 5'-diphosphate ribose (cADPR) analogs based on

72 Stable cyclic adenosine 5'-diphosphate ribose (cADPR) analogues are ch

73 (2+)-mobilising messengers, including cyclic adenosine 5'-diphosphate ribose (cADPR), and CD38 knocko

74 Inositol trisphosphate (InsP3) and cyclic adenosine 5'-diphosphate-ribose (cADPR) are established

75 ne negativity, annexin positivity, and poly (adenosine 5'-diphosphate-ribose) polymerase cleavage.

76 that GzmA cleaves the DNA damage sensor poly(adenosine 5'-diphosphate-ribose) polymerase-1 (PARP-1) a

77 ition, according to the crystal structure of adenosine-5-diphosphate-ribose (ADP-ribose) in complex w

78 mitant with this blocking, cleavage of poly (adenosine 5'-diphosphate--ribose) polymerase and activat

79 3 and induced caspase 3 activation, poly(ADP[adenosine 5'-diphosphate]-ribose) polymerase (PARP) clea

80 vidence suggests that the peroxynitrite-poly-adenosine 5'-diphosphate ribosyl polymerase pathway cont

81 equent activation of the nuclear enzyme poly-adenosine 5'-diphosphate ribosyl synthetase, and eventua

82 x group in the phosphorylated state with the adenosine-5-diphosphate-ribosylarginine (ADP-RA) complex

83 their attention to endocytosis and show that adenosine 5'-diphosphate-ribosylation factor 6 (Arf6) pl

84 coupled with immunodetection methods and an adenosine 5(')-diphosphate-ribosylation assay to measure

85 '-triphosphate, uridine 5'-triphosphate, and adenosine 5'-diphosphate significantly increased prolife

86 ubendothelium under high shear, they release adenosine-5'-diphosphate that acts in a positive feedbac

87 In response to adenosine 5'-diphosphate, the P2Y1 receptor (P2Y1R) faci

88 ignaling mechanisms in platelets mediated by adenosine-5'-diphosphate through the P2Y(12) receptor.

89 ATP site and 2'(3')-O-(2,4,6-trinitrophenyl)adenosine 5'-diphosphate (TNP-ADP) was used to probe the

90 sence of ATP, 2'(3')-O-(2,4,6-trinitrophenyl)adenosine 5'-diphosphate (TNP-AMP), or an fluoroisothioc

91 ting concentrations of fibrillar collagen or adenosine 5'-diphosphate, uniquely assemble an IQGAP2/ar

92 Microvessel relaxation response to adenosine 5'-diphosphate was improved in the HCW group a

93 nd that of the agonists ADP and 2-methylthio-adenosine-5'-diphosphate, was reduced.